Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy

• Martina S. J. McDermott,
• Brigid C. Browne,
• Neil T. Conlon,
• Neil A. O’Brien,
• Dennis J. Slamon,
• Michael Henry,
• Paula Meleady,
• Martin Clynes,
• Paul Dowling,
• John Crown,
• Norma O’Donovan

Affiliations

Martina S. J. McDermott

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Brigid C. Browne

Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research Sydney

Neil T. Conlon

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Neil A. O’Brien

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles

Dennis J. Slamon

Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles

Michael Henry

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Paula Meleady

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Martin Clynes

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Paul Dowling

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

John Crown

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University

Norma O’Donovan

Molecular Therapeutics for Cancer Ireland, National Institute for Cellular Biotechnology, Dublin City University